Glipizide; rosiglitazone maleate
Проводит ГлаксоСмитКляйн ЛЛС
Страница компанииA Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00116831/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 30–80 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 672 чел. во всех странах исследования.
- Плановая дата окончания (08.2008) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 8 · невключение: 24
Критерии включения
- Male or female between 30 to 80 years of age, inclusive.
- Established diagnosis of T2DM (based on diagnostic criteria of the American Diabetes Association (ADA), WHO guidelines or local national guidelines).
- Subjects who are undergoing coronary angiography for evaluation of suspected or previously diagnosed coronary artery disease or who are undergoing PCI.
- Subjects' prior anti-hyperglycemic diabetic therapy:
- Diet and exercise only (drug naïve), with HbA1c >7.0 and £ 10.0%. HbA1c > 6.5 and <= 8.5%.
- Left ventricular ejection fraction (EF) ³ 40% as assessed by contrast ventriculography (or previously documented in medical notes within one month prior to index procedure by other methods e.g. echocardiography or nuclear study)
- Female subjects must be postmenopausal (i.e., >6 months without menstrual period), surgically sterile, or using effective contraceptive measures (oral contraceptives, Norplant, Depo-Provera, an intra-uterine device (IUD), a diaphragm with spermicide or a condom with spermicide). Women of childbearing potential must use effective contraceptive measures for at least 1 month prior to visit 1a, and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study medication.
- Willingness and ability to give informed consent prior to entering the study and available to complete the study.
Критерии невключения
- Type 1 diabetes and/or history of diabetic ketoacidosis.
- Exposure to a TZD or other PPAR-g agonist within the 6 months prior to screening visit.
- Subjects treated with triple OAD therapy or high dose dual combination OAD therapy \[1\].
- Subjects who have required chronic insulin use in the last 6 months (except during pregnancy or acute episodes such as hospitalization, trauma or infection).
- ST segment elevation myocardial infarction in the last 30 days.
- Subjects who have a history or are scheduled to receive coronary artery bypass graft surgery (CABG), valve repair or replacement, aneurysmectomy or planned major non-cardiac surgery during the study period.
- Subjects who have severe cardiac valvular disease
- Stroke or resuscitated in the past 6 months
- History of congestive heart failure (NYHA class I - IV)
- History of significant hypersensitivity or reaction (e.g., difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to any TZD, SU, biguanide or insulin
- Prior history of severe edema or edema requiring medical treatment.
- Chronic disease requiring chronic or intermittent treatment with oral, intravenous, or injected corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).
- Recent history or suspicion of current drug abuse or alcohol abuse within the last 6 months.
- Untreated hypo- or hyperthyroidism
- A diagnosis of cancer (other than superficial squamous, basal cell skin cancer, or adequately treated cervical carcinoma in situ) in the past 3 years or current treatment for the active cancer.
- Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgement of the Investigator, would preclude safe completion of the study.
- Blood pressure: SBP >170 or DBP > 100 mmHg
- Significant anemia (Hemoglobin < 11 g/dL for males and < 10 g/dL for females).
- Significant renal disease manifested by serum creatinine (> 1.5mg/dL for males or > 1.4mg/dL for females), or where the use of metformin is contra-indicated.
- Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 2.5 times upper limit of normal (ULN) or bilirubin >2x ULN).
- History of myopathy or history of elevated creatine kinase (CK) > 3 times upper normal limit.
- Use of an investigational drug within 30 days or 5 half-lives (whichever is the longer).
- Women who are lactating, pregnant or planning to become pregnant during the course of the study.
- Unwillingness or inability to comply with the procedures described in this protocol.
Источник: ClinicalTrials.gov, NCT00116831 · запись обновлена в реестре 23 марта 2017.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 34
- Change From Baseline in Percent Atheroma Volume (PAV) to Month 18 — Baseline to Month 18
- Model Adjusted Change From Baseline in Percent Atheroma Volume (PAV) to Month 18 — Baseline to Month 18
Цель исследования
The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00116831 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.